SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

Antimicrob Agents Chemother. 2000 May;44(5):1159-62. doi: 10.1128/AAC.44.5.1159-1162.2000.

Abstract

Ramichloridium obovoideum ("Ramichloridium makenziei") is a rare cause of lethal cerebral phaeohyphomycosis. It has been, so far, geographically restricted to the Middle East. BALB/c mice were inoculated with two strains of R. obovoideum intracranially. Therapy with amphotericin B, itraconazole, or the investigational triazole SCH 56592 was conducted for 10 days. Half the mice were monitored for survival and half were killed for determination of the fungal load in brain tissue. Recipients of SCH 56592 had significantly prolonged survival and lower brain fungal burden, and this result was found for mice infected with both of the fungal strains tested. Itraconazole reduced the brain fungal load in mice infected with one strain but not the other, while amphotericin B had no effect on brain fungal concentrations. This study indicates a possible role of SCH 56592 in the treatment of the serious cerebral phaeohyphomycosis due to R. obovoideum.

MeSH terms

  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / therapeutic use*
  • Ascomycota* / drug effects
  • Central Nervous System Fungal Infections / drug therapy*
  • Central Nervous System Fungal Infections / microbiology
  • Disease Models, Animal
  • Female
  • Itraconazole / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred ICR
  • Mycoses / drug therapy*
  • Mycoses / microbiology
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • Itraconazole
  • posaconazole
  • Amphotericin B